Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03126110
Title Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Corporation

endometrial cancer

esophageal cancer

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

stomach cancer


INCAGN01876 + Ipilimumab + Nivolumab

INCAGN01876 + Nivolumab

INCAGN01876 + Ipilimumab

Age Groups: adult | senior
Covered Countries USA | ESP | BEL

No variant requirements are available.